This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilo triacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with a galactosamine chain or lactose chain is disclosed. In particular, only one amino acid L-lysine is involved to provide trivalency. All carboxyl groups in N
ε
-benzyloxycarbonyl-N
α
-dicarboxymethyl-L-lysine can be conjugated with three glycosides of ahGalNAc or ahLac in one step. This invention also provides a hexa-lactoside. In particular, the TFA-AHA-Asp was used to conjugate 2 moles of NTA(ahLac)
3
. This invention also provides a method for adding a spacer between NTA and DTPA. The extended hepatocyte-specific glyco-ligand has higher
111
In-radiolabelling yield than those non-extended.
该发明提供了新型的肝靶向药物及其合成方法。一种肝靶向药物,以赖
氨酸为骨架,具有
氨基
三乙酸结构,通过与糖苷基团形成多价性,与半
乳糖胺链或
乳糖链结合。具体来说,仅涉及一种
氨基酸L-赖氨酸,以提供三价性。Nε-苄氧羰基-Nα-二羧甲基-
L-赖氨酸中的所有羧基可以在一步中与三个ahGalNAc或ahLac的糖苷结合。该发明还提供了一种六
乳糖苷。具体来说,TFA-AHA-Asp被用于将2摩尔的
NTA(ahLac)3结合。该发明还提供了一种在
NTA和
DTPA之间添加间隔物的方法。扩展的肝细胞特异性糖基
配体的111In标记产率高于非扩展的
配体。